175 related articles for article (PubMed ID: 15157004)
1. Review of health economics modelling in rheumatoid arthritis.
Emery P
Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
[TBL] [Abstract][Full Text] [Related]
3. Thoughts on health economics in rheumatoid arthritis.
Kobelt G
Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii35-9. PubMed ID: 17934092
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies.
Kumar S; Bagepally BS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1027-1040. PubMed ID: 37604704
[TBL] [Abstract][Full Text] [Related]
5. Management of Rheumatoid Arthritis in Primary Care: A Scoping Review.
Inchingolo F; Inchingolo AM; Fatone MC; Avantario P; Del Vecchio G; Pezzolla C; Mancini A; Galante F; Palermo A; Inchingolo AD; Dipalma G
Int J Environ Res Public Health; 2024 May; 21(6):. PubMed ID: 38928909
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomics: friend or foe?
Drummond M
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii44-7. PubMed ID: 17038472
[TBL] [Abstract][Full Text] [Related]
7. Cost of treating rheumatoid arthritis in the primary care public health system in Ireland: A time-driven activity-based cost analysis.
Kenny C; Chavrimootoo S; Priyadarshini A
Explor Res Clin Soc Pharm; 2024 Jun; 14():100439. PubMed ID: 38655193
[TBL] [Abstract][Full Text] [Related]
8. A Review of the Use of Biological Agents in Human Immunodeficiency Virus Positive Patients With Rheumatological Diseases.
Attallah MA; Jarrin Jara MD; Gautam AS; Peesapati VSR; Khan S
Cureus; 2020 Oct; 12(10):e10970. PubMed ID: 33209528
[TBL] [Abstract][Full Text] [Related]
9. Modeling rheumatoid arthritis using different techniques - a review of model construction and results.
Scholz S; Mittendorf T
Health Econ Rev; 2014 Dec; 4(1):18. PubMed ID: 26208921
[TBL] [Abstract][Full Text] [Related]
10. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting May 17-18, 2022.
Kay J; Nikolov NP; Weisman MH;
Arthritis Rheumatol; 2024 Apr; ():. PubMed ID: 38622107
[TBL] [Abstract][Full Text] [Related]
11. Targeting Therapeutic Windows for Rheumatoid Arthritis Prevention.
Gao KX; Yang YH; Liang Q; Mei LY; Liang YB; Wang MJ; Chen XM; Huang QC; Wen ZH; Huang RY
Chin J Integr Med; 2024 May; ():. PubMed ID: 38753276
[TBL] [Abstract][Full Text] [Related]
12. Using LASSO Regression to Predict Rheumatoid Arthritis Treatment Efficacy.
Odgers DJ; Tellis N; Hall H; Dumontier M
AMIA Jt Summits Transl Sci Proc; 2016; 2016():176-83. PubMed ID: 27570666
[TBL] [Abstract][Full Text] [Related]
13. 'Editorial: Advancements and Challenges in Cost and Resource Allocation: 2022.
Hafidz F; Sampson C
Front Health Serv; 2023; 3():1254318. PubMed ID: 37546167
[No Abstract] [Full Text] [Related]
14. The Sheffield rheumatoid arthritis health economic model.
Tosh J; Brennan A; Wailoo A; Bansback N
Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv26-31. PubMed ID: 21859702
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.
Puolakka K; Blåfield H; Kauppi M; Luosujärvi R; Peltomaa R; Leikola-Pelho T; Sennfalt K; Beresniak A
Open Rheumatol J; 2012; 6():38-43. PubMed ID: 22582103
[TBL] [Abstract][Full Text] [Related]
17. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
18. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
19. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
Eriksson JK; Neovius M; Bratt J; Petersson IF; van Vollenhoven RF; Geborek P; Ernestam S
JAMA Intern Med; 2013 Aug; 173(15):1407-14. PubMed ID: 23817631
[TBL] [Abstract][Full Text] [Related]
20. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
